Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Infectious disease

HBV

Not applicable

Rodent studies suggest the addition of Baraclude entecavir to plasmid- and adenoviral vector-based vaccination protocols could help treat chronic HBV infection. In woodchucks chronically infected with woodchuck hepatitis virus (WHV), pretreatment with entecavir followed by injection of a DNA vaccine encoding WHV core antigen led to a more potent antiviral immune response than either treatment alone. Next steps could include developing an analogous vaccine candidate for HBV and evaluating it using the same protocol in combination with entecavir.
Bristol-Myers Squibb Co. markets Baraclude, a cyclopentile guanosine nucleoside analog, to treat HBV infection.

SciBX 6(28); doi:10.1038/scibx.2013.726
Published online July 25, 2013

Patent and licensing status unavailable

Kosinska, A.D. et al. PLoS Pathog.; published online June 13, 2013;
doi:10.1371/journal.ppat.1003391
Contact: Michael Roggendorf, Essen University Hospital, Essen, Germany
e-mail:
michael.roggendorf@uni-due.de